Sustained in vivo regression of Dunning H rat prostate cancers treated with combinations of androgen ablation and trk tyrosine kinase inhibitors, CEP-751 (KT-6587) or CEP-701 (KT-5555)

Cancer Research

Volumn 59, Issue 10, 1999, Pages 2395-2401

  George, Daniel J ^a   Dionne, Craig A ^c   Jani, Jitesh ^c   Angeles, Thelma ^c   Murakata, Chikara ^b   Lamb, John ^a   Isaacs, John T ^a  

^a JOHNS HOPKINS UNIVERSITY   (United States)

^b KYOWA HAKKO KOGYO CO LTD   (Japan)

^c CEPHALON INC   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ANDROGEN; CEP 701; CEP 751; LEUPRORELIN; PROTEIN TYROSINE KINASE INHIBITOR; UNCLASSIFIED DRUG;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANTINEOPLASTIC ACTIVITY; ARTICLE; CANCER GROWTH; CANCER INHIBITION; CANCER REGRESSION; CASTRATION; CONTROLLED STUDY; DRUG EFFICACY; DRUG POTENCY; DRUG SELECTIVITY; IMMUNOHISTOCHEMISTRY; NONHUMAN; ORAL DRUG ADMINISTRATION; PRIORITY JOURNAL; PROSTATE CANCER; RAT; TUMOR VOLUME;

ADENOCARCINOMA; ADMINISTRATION, ORAL; ANDROGENS; ANIMALS; ANTINEOPLASTIC AGENTS; ANTINEOPLASTIC AGENTS, HORMONAL; CARBAZOLES; COMBINED MODALITY THERAPY; DRUG SCREENING ASSAYS, ANTITUMOR; DRUG SYNERGISM; INDOLES; INJECTIONS, SUBCUTANEOUS; LEUPROLIDE; MALE; NEOPLASM PROTEINS; NEOPLASM TRANSPLANTATION; NEOPLASMS, HORMONE-DEPENDENT; ORCHIECTOMY; PROSTATIC NEOPLASMS; PROTO-ONCOGENE PROTEINS; RATS; RECEPTOR PROTEIN-TYROSINE KINASES; RECEPTOR, TRKA; RECEPTORS, NERVE GROWTH FACTOR;

EID: 0033563119     PISSN: 00085472     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (26)

1. Crawford, E. D., Eisenberger, M. A., Mcleod, D. G., Spaulding, J. T., Benson, M., Door, R. A., Blumenstein, B. A., Davis, M. A., and Goodman, P. J. A controlled trial of Leuprolide with and without flutamide in prostatic carcinoma. N. Engl. J. Med., 321: 419-424, 1989.
2. Parker, S. L., Tong, T., Bolden, S., and Wingo, P. A. Cancer Statisics, 1997. CA Cancer J. Clin., 47: 5-27, 1997.
3. Djakiew, D., Delsite, R., Pflug, B. R., Wrathall, J., Lynch, J. H., and Onoda, M. Regulation of growth by a nerve growth factor-like protein which modulates paracrine interactions between a neoplastic epithelial cell line and stromal cells of the human prostate. Cancer Res., 51: 3304-3310, 1991.
4. Djakiew, D. Role of nerve growth factor-like protein in the paracrine regulation of prostate growth. J. Androl., 13: 476-487, 1992.
5. Dionne, C. A., Jani, J., Camoratto, A. M., Emerson, E., Neff, N. T., Vaught, J., Murakata, C., Djakiew, D., Lamb, J., Dalrymple, S., George, D., and Isaacs, J. T. Cell cycle independent death of prostate adenocarcinoma is induced by the Trk tyrosine kinase inhibitor, CEP-751. Clin. Cancer Res., 4: 1887-1898, 1998.
6. Graham, C. W., Lynch, J. H., and Djakiew, D. Distribution of nerve growth factor-like protein and nerve growth factor receptor in human benign prostatic hyperplasia and prostatic adenocarcinoma. J. Urol., 147: 1444-1447, 1992.
7. MacGrogan, D., Saint-Andre, J-P., and Dicou, E. Expression of nerve growth factor receptor genes in human tissues and in prostatic adenocarcinoma cell lines. J. Neurochem., 59: 1381-1391, 1992.
8. Pflug, B. R., Dionne, C., Kaplan, D. R., Lynch, J., and Djakiew, D. Expression of a Trk high affinity nerve growth factor receptor in the human prostate. Endocrinology, 136: 262-268, 1995.
9. Paul, A. B., Grant, E. S., and Habib, F. K. The expression of β-nerve growth factor (β-NGF) in benign and malignant human prostate tissue: relationship to neuroendocrine differentiation. Br. J. Cancer, 74: 1990-1996, 1996.
10. George, D. A., Susuki, H., Bova, G. S., and Isaacs, J. T. Mutational analysis of the trkA gene in prostate cancer. Prostate, 36: 172-180, 1998.
11. Djakiew, D., Pflug, B. R., Delsite, R., Onoda, M., Lynch, J. H., Arand, G., and Thompson, E. W. Chemotaxis and chemokinesis of human prostate tumor cell lines in response to human prostate stromal cell secretory proteins containing nerve growth factor-like protein. Cancer Res., 53: 1416-1420, 1993.
12. Geldof, A. A., De Kleijn, M. A. T., Rao, B. R., and Newling, D. W. W. Nerve growth factor stimulates in vivo invasive capacity of DU 145 human prostatic cancer cells. J. Cancer Res. Clin. Oncol., 123: 107-112, 1997.
13. Pflug, B. R., Onoda, M., Lynch, J. H., and Djakiew, D. Reduced expression of the low affinity nerve growth factor receptor in benign and malignant human prostate tissue and loss of expression in four human metastatic prostate tumor cell lines. Cancer Res., 52: 5403-5406, 1992.
14. Berg, M. M., Sternberg, D. W., Parada, L. F., and Chao, M. V. K-252a inhibits nerve growth factor-induced Trk proto-oncogene tyrosine phosphorylation and kinase activity. J. Biol. Chem., 267: 13-16, 1992.
15. Nye, S. H., Squinto S. P., Glass, D. J., Stitt, T. N., Hantzopoulos, P., Macchi, M. J., Lindsay, N. S., Ip, N. Y., and Yancopoulos, G. K-252a and staurosporine selectively block autophosphorylation of neurotrophin receptors and neurotrophin-mediated responses. Mol. Biol. Cell., 3: 677-686, 1992.
16. Ohmichi, M., Decker, S. J., Pang, L., and Saltiel, A. R. Inhibition of the cellular actions of nerve growth factor by staurosporine and K252a results from the attenuation of the activity of the Trk tyrosine kinase. Biochemistry, 31: 4034-4039, 1992.
17. Tapley, P., Lambelle, F., and Barbacid, M. K252a is a selective inhibitor of the tyrosine protein kinase activity of the Trk family of oncogenes and neurotrophin receptors. Oncogene, 7. 371±381, 1992.
18. Camoratto, A. M., Jani, J. P., Angeles, T. S., Maroney, A. C., Sanders, C. Y., Murakata, C., Neff, N. T., Vaught, J. L., Isaacs, J. T., and Dionne, C. A. CEP-751 inhibits Trk receptor tyrosine kinase activity in vitro and exhibits anti-tumor activity. Int. J. Cancer, 72: 673-679, 1997.
19. Isaacs, J. T. Relationship between tumor size and curability of prostatic cancer by combined chemo-hormonal therapy in rats. Cancer Res., 49: 6290-6294, 1989.
20. Isaacs, J. T., and Coffey, D. S. Adaptation versus selection as the mechanism responsible for the relapse of prostatic cancer to androgen ablation therapy as studies in the Dunning R-3327-H adenocarcinoma. Cancer Res., 41: 5070-5075, 1981.
21. 2 domains of phospholipase C gamma. EMBO J., 11: 559-567, 1992.
22. Angeles, T. S., Steffler, C., Bartlett, B. A., Hudkins, R. L., Stephens, R. M., Kaplan, D. R., and Dionne, C. A. Enzyme-linked immunosorbent assay for trkA tyrosine kinase activity. Anal. Biochem., 236: 49-55, 1996.
23. Pitt, A. M., and Lee, C. High throughput screening protein kinase assays optimized for reaction, binding, and detection totally within a 96-well plate. J. Biomol. Screening, 1: 47-51, 1996.
24. Kyprianou, N., and Isaacs, J. T. Quantal relationship between prostatic dihydrotest-osterone and prostatic cell content: critical threshold concept. Prostate, 10: 41-50, 1987.
25. Zaccheo, T., Giudici, D., and di Salle, E. Effect of Turosteride, a 5α-reductase inhibitor, on the Dunning R3327 rat prostatic carcinoma. Prostate, 30: 85-91, 1997.
26. Chrisp, P., and Sorkin, E. M. Leuprolide. A review of its pharmacology and therapeutic use in prostatic disorders. Drugs Aging, 1: 487-509, 1991.